Denosumab is a fully human monoclonal antibody to receptor activator of nuclear factor
kappa-B ligand (RANKL), a cytokine member of the tumor necrosis factor family that is the …

Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal
osteoporosis. Phase 2 data indicate that 50 mg once weekly inhibits bone resorption and …

Receptor activator of nuclear factor-κB ligand (RANKL) is a cytokine essential for osteoclast
differentiation, activation, and survival. Denosumab, a human monoclonal antibody against …

Introduction Osteoporosis is a significant public health issue affecting over half of women
aged over 50. With an aging population, its importance is set to increase further over time …

Abstract Background and Objective: Inhibition of the receptor activator of nuclear factor kB
ligand (RANKL) is a therapeutic target for treatment of bone disorders associated with …

Osteoporosis represents a weakening of bone tissue due to an imbalance in the dynamic
processes of bone formation and bone resorption that are continually ongoing within bone …

Anti-resorptive therapy is the principal means of treating osteoporotic disorders. The two
families of presently available anti-resorptive drugs, namely bisphosphonates and …

Osteoporosis is age-related deterioration in bone mass and micro-architecture. Denosumab
is a novel human monoclonal antibody for osteoporosis. It is a receptor activator of nuclear …

More than a decade ago, receptor activator of nuclear factor-κB ligand (RANKL) was
identified as the key molecule mediating osteoclast development, activity, and survival. 1 …

The receptor activator of NF-κB ligand (RANKL) is a member of the TNF receptor
superfamily, essential for osteoclastogenesis. It binds to its receptor activator of NF-κB on the …